← SynDRA
FOSAPREPITANT
SynDRA canonical compound SYN0022909 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TACR1 |
|---|
| Mechanism of action | tachykinin antagonist |
|---|
| Indication | nausea | vomiting |
|---|
| Disease area | gastroenterology |
|---|
All known targets
- TACR1
- CYP2C19
- CYP3A4
- TACR3
Mechanisms of action (all sources)
- TACR1 ANTAGONIST
- Neurokinin 1 receptor antagonist
- tachykinin antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Neurokinin 1 Antagonists
- Antiemetics
- Central Nervous System Agents
- Gastrointestinal Agents
- Neurokinin-1 Receptor Antagonists
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Substance P/Neurokinin-1 Receptor Antagonist
- Cytochrome P450 3A4 Inhibitors
- Cytochrome P450 3A4 Inducers
- Cytochrome P450 2C9 Inducers
ATC classes
- A04A · ANTIEMETICS AND ANTINAUSEANTS
Cross-references
Synonyms
- EMEND
- FOCINVEZ
- FOSAPREPITANT DIMEGLUMINE
- Focinvez
- ivemend
- fosaprepitant dimeglumine
- fosaprepitant meglumine
- L-758298
- Ivemend
- fosaprepitantum
- 6L8OF9XRDC
- L 758298
- L-758,298
- CHEBI:64321
- L785,298
- RefChem:57105
- DTXCID801506659
- Fosaprepitant [INN]
- Fosaprepitant (INN)
- UNII-6L8OF9XRDC
- Fosaprepitant [INN:BAN]
- Fosaprepitant Dimeglumine
- FOSAPREPITANT [MI]
- FOSAPREPITANT [VANDF]
- FOSAPREPITANT [MART.]
- SCHEMBL309491
- FOSAPREPITANT [WHO-DD]
- GTPL7623
- SCHEMBL1651366
- FOSAPREPITANT [EMA EPAR]
- EX-A1255A
- BARDROPHSZEBKC-OITMNORJSA-O
- GLXC-05084
- EBC-27390
- NSC794608
- AKOS025149465
- CS-1760
- NSC-794608
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Angioedema
- Asthenia
- Bradycardia
- Constipation
- Dizziness
- Fatigue
- Headache
- Hiccups
- Tinnitus
- Infestation
Look up FOSAPREPITANT in the interactive SynDRA portal →